Core Insights - Humacyte, Inc. presented significant findings on its acellular tissue engineered vessel (ATEV™) at the VEITHsymposium, highlighting its potential in vascular applications and regenerative medicine [1][2][3] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][8] - The company received FDA approval for its ATEV in December 2024 for vascular trauma indications and is conducting late-stage clinical trials for other vascular applications [8] ATEV Performance and Clinical Outcomes - ATEV demonstrated the ability to remodel into living vascular tissue, showing progressive recellularization with host cells, which is crucial for its function as a vascular graft [2][3] - In a study involving dialysis patients with Steal syndrome, ATEV showed durable patency and safety, with no graft-related infections or ruptures observed over a follow-up period of up to 35.9 months [3][4] - ATEV was reported to have superior patency and duration of use over two years compared to autogenous fistula in female patients, a subgroup with historically poor outcomes [10] Additional Research Findings - Presentations at the symposium included positive outcomes for ATEV in treating torso arterial trauma and high rates of limb salvage in trauma patients treated under humanitarian programs in Ukraine [4][10] - The ATEV's performance in complex cases suggests it could serve as a biologic alternative when autologous vein is not available, moving towards regenerative solutions in vascular surgery [4][5] Future Directions - Humacyte is exploring additional applications for ATEV, including coronary artery bypass grafts and treatment for type 1 diabetes, indicating a broadening scope of its innovative tissue engineering technology [8]

Core Insights - Holiday shoppers are increasingly relying on credit cards, with 42% naming it their preferred payment method, up from 38% last year [1] - The majority of Americans (57%) expect to spend the same or more this holiday season compared to last year, with 58% planning to spend over $250, an increase from 56% last year [2][3] - Optimism about household finances remains stable, with 55% of Americans expressing a positive outlook, although this is a slight decline from 58% last year [6] Consumer Spending Trends - 41% of consumers plan to shop online between Thanksgiving and Cyber Monday, while 33% intend to shop in person during that weekend [1] - Among different generations, 64% of Millennials and 63% of Gen X expect to spend more than $250 this holiday season, compared to 54% of Boomers [3] Credit Card Usage - Nearly 175 million Americans hold one or more active credit cards, indicating strong consumer demand for credit [5] - 30% of consumers plan to apply for new credit or refinance existing credit within the next year, with 55% of those intending to apply for a new credit card [11] Financial Concerns - Inflation remains the top financial worry for consumers, with 81% citing it as a major concern, followed by recession (52%) and housing prices (43%) [7] - 48% of Americans expect their income to increase in the next 12 months, a decline from 53% last year, with 86% expressing concern over potential trade tariffs [8] Credit Monitoring and Education - TransUnion launched Credit Essentials, offering free credit management tools to help consumers monitor their credit and receive tailored credit offers [12][13] - Over half of Americans (55%) check their credit report at least monthly, with 95% acknowledging the importance of monitoring their credit [14]

Hydrochemolytic™ oil was processed “as is” without hydrotreatment or dilution achieved stable furnace operation, and olefin yields comparable to conventional liquid feedstocks, validating its potential as a drop-in-compatible circular feedstock for steam crackersLONDON, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste ...

The Companies Intend to Advance 1 SOLO Reactor Pilot with Expansion Option of 100 SOLOs to Power Uvation’s Rapidly Growing Data-Center EcosystemNEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Terra Innovatum Global N.V. ("Terra Innovatum" or the “Company”) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors and Uvation Inc., an integrated technology provider enabling global AI infrastructure and specializing in the development of large-scale datacenters engineered to support dense, high-performance AI ...

RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will participate in the following investor conferences. BTIG 5th Annual Ophthalmology Day (Virtual): Ash Jayagopal, PhD, MBA, Chief Scientific and Development Officer, will participate ...

Accessibility StatementSkip Navigation Conference call will be held on November 27, 2025 at 11 AM ET TORONTO, Nov. 20, 2025 /PRNewswire/ -- Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) and its wholly-owned subsidiary Zoomd Ltd. (collectively, "Zoomd" or the "Company"), the marketing technology (MarTech) user-acquisition and engagement platform, announced today that it expects to report its financial results for the third quarter on November 27, 2025. The Company has scheduled a conference call on th ...

GIG HARBOR, Wash., Nov. 20, 2025 (GLOBE NEWSWIRE) -- IP Strategy (the “Company”) (Nasdaq: IPST), the first company to adopt a treasury reserve policy centered on the $IP token powered by the Story AI-native blockchain network, today announced that it has received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and that the Company’s prior deficiency is now closed. ...

AUSTIN, TX and DURHAM, NC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-mediated diseases, today announced that Company management will participate in multiple investor conferences in December 2025. Conference Details Conference: Piper Sandler 37th A ...

Geneva, Switzerland, Nov. 20, 2025 (GLOBE NEWSWIRE) -- A special event will be held at the Las Vegas Grand Prix to celebrate the commercial launch of SEALSQ's QS7001 quantum resistant chip, on November 21st at F1 Arcade as motorsport takes over the city. SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, and BWT Alpine Formula One Team today announced an exciting, new partnersh ...

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment Advances, with EMA Guidance Supporting a Single Nebokitug Phase 3 Registration Trial Using a Clinical Event Composite Endpoint— —Phase 2 SPRING Trial OLE Data Showing Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks Presented at AASLD 2025— —New Clinical Data Presented at AASLD 2025 Provides Insights on Nebokitug’s Direct Macrophage-Med ...